Rhenman & Partners Asset Management AB as of Dec. 31, 2015
Portfolio Holdings for Rhenman & Partners Asset Management AB
Rhenman & Partners Asset Management AB holds 96 positions in its portfolio as reported in the December 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Perrigo Company (PRGO) | 3.2 | $21M | 145k | 144.70 | |
| Abiomed | 3.0 | $20M | 220k | 90.28 | |
| Medtronic (MDT) | 2.9 | $19M | 249k | 76.92 | |
| Alexion Pharmaceuticals | 2.9 | $19M | 100k | 190.75 | |
| CVS Caremark Corporation (CVS) | 2.7 | $18M | 180k | 97.77 | |
| Allergan | 2.6 | $17M | 55k | 312.51 | |
| Abbvie (ABBV) | 2.2 | $15M | 246k | 59.24 | |
| UnitedHealth (UNH) | 2.1 | $14M | 121k | 117.64 | |
| Pfizer (PFE) | 2.1 | $14M | 438k | 32.28 | |
| Amgen (AMGN) | 2.0 | $13M | 82k | 162.33 | |
| CIGNA Corporation | 1.9 | $13M | 87k | 146.33 | |
| Bristol Myers Squibb (BMY) | 1.9 | $13M | 183k | 68.79 | |
| Gilead Sciences (GILD) | 1.9 | $13M | 124k | 101.19 | |
| Alkermes (ALKS) | 1.9 | $13M | 158k | 79.38 | |
| Celgene Corporation | 1.9 | $13M | 104k | 119.76 | |
| BioMarin Pharmaceutical (BMRN) | 1.9 | $12M | 118k | 104.76 | |
| Eli Lilly & Co. (LLY) | 1.9 | $12M | 146k | 84.26 | |
| Anthem (ELV) | 1.9 | $12M | 88k | 139.44 | |
| Incyte Corporation (INCY) | 1.8 | $12M | 110k | 108.45 | |
| McKesson Corporation (MCK) | 1.8 | $12M | 59k | 197.24 | |
| Regeneron Pharmaceuticals (REGN) | 1.7 | $11M | 21k | 542.86 | |
| Aetna | 1.7 | $11M | 104k | 108.12 | |
| Walgreen Boots Alliance | 1.7 | $11M | 132k | 85.15 | |
| Zimmer Holdings (ZBH) | 1.7 | $11M | 107k | 102.59 | |
| Humana (HUM) | 1.6 | $11M | 61k | 178.51 | |
| St. Jude Medical | 1.6 | $11M | 175k | 61.77 | |
| Becton, Dickinson and (BDX) | 1.6 | $11M | 69k | 154.09 | |
| Laboratory Corp. of America Holdings | 1.5 | $10M | 81k | 123.64 | |
| Centene Corporation (CNC) | 1.5 | $9.8M | 149k | 65.81 | |
| Nektar Therapeutics | 1.5 | $9.8M | 581k | 16.85 | |
| Cardinal Health (CAH) | 1.4 | $9.3M | 104k | 89.27 | |
| Dex (DXCM) | 1.3 | $8.6M | 105k | 81.90 | |
| Health Net | 1.3 | $8.4M | 122k | 68.46 | |
| Medivation | 1.2 | $7.7M | 160k | 48.34 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.1 | $7.0M | 56k | 125.82 | |
| Halozyme Therapeutics (HALO) | 1.1 | $7.1M | 410k | 17.33 | |
| Endo International | 1.1 | $7.1M | 116k | 61.22 | |
| Valeant Pharmaceuticals Int | 1.1 | $7.0M | 69k | 101.65 | |
| Cempra | 1.1 | $7.0M | 226k | 31.13 | |
| Intra Cellular Therapies (ITCI) | 1.0 | $6.8M | 126k | 53.79 | |
| Hca Holdings (HCA) | 1.0 | $6.5M | 96k | 67.62 | |
| Express Scripts Holding | 1.0 | $6.5M | 74k | 87.41 | |
| Keryx Biopharmaceuticals | 0.9 | $6.2M | 1.2M | 5.05 | |
| Jazz Pharmaceuticals (JAZZ) | 0.9 | $5.9M | 42k | 140.57 | |
| Revance Therapeutics | 0.9 | $5.9M | 173k | 34.16 | |
| Alnylam Pharmaceuticals (ALNY) | 0.9 | $5.8M | 62k | 94.15 | |
| Rite Aid Corporation | 0.8 | $5.3M | 678k | 7.84 | |
| Universal Health Services (UHS) | 0.8 | $5.3M | 44k | 119.50 | |
| Boston Scientific Corporation (BSX) | 0.8 | $5.1M | 274k | 18.44 | |
| Celldex Therapeutics | 0.8 | $5.0M | 320k | 15.68 | |
| Cerner Corporation | 0.8 | $4.9M | 82k | 60.17 | |
| Cooper Companies | 0.8 | $5.0M | 37k | 134.19 | |
| AmerisourceBergen (COR) | 0.7 | $4.8M | 46k | 103.72 | |
| Lion Biotechnologies | 0.7 | $4.4M | 575k | 7.72 | |
| ACADIA Pharmaceuticals (ACAD) | 0.7 | $4.3M | 120k | 35.65 | |
| Endologix | 0.6 | $4.2M | 420k | 9.90 | |
| Ionis Pharmaceuticals (IONS) | 0.6 | $4.1M | 67k | 61.93 | |
| Edwards Lifesciences (EW) | 0.6 | $3.9M | 49k | 78.98 | |
| Supernus Pharmaceuticals (SUPN) | 0.6 | $3.9M | 288k | 13.44 | |
| Intercept Pharmaceuticals In | 0.6 | $3.9M | 26k | 149.35 | |
| Livanova Plc Ord (LIVN) | 0.6 | $3.9M | 66k | 59.36 | |
| Insulet Corporation (PODD) | 0.6 | $3.6M | 96k | 37.81 | |
| Zeltiq Aesthetics | 0.6 | $3.7M | 128k | 28.53 | |
| Baxalta Incorporated | 0.5 | $3.4M | 88k | 39.03 | |
| HeartWare International | 0.5 | $3.4M | 67k | 50.40 | |
| Portola Pharmaceuticals | 0.5 | $3.2M | 62k | 51.45 | |
| Horizon Pharma | 0.5 | $3.2M | 146k | 21.67 | |
| Macrogenics (MGNX) | 0.4 | $2.9M | 94k | 30.97 | |
| Achillion Pharmaceuticals | 0.4 | $2.9M | 266k | 10.79 | |
| Cepheid | 0.4 | $2.7M | 75k | 36.53 | |
| Ariad Pharmaceuticals | 0.4 | $2.7M | 430k | 6.25 | |
| Pacira Pharmaceuticals (PCRX) | 0.4 | $2.7M | 35k | 76.80 | |
| Tesaro | 0.4 | $2.7M | 51k | 52.32 | |
| Xencor (XNCR) | 0.4 | $2.7M | 181k | 14.62 | |
| Exelixis (EXEL) | 0.4 | $2.6M | 460k | 5.64 | |
| Rigel Pharmaceuticals | 0.4 | $2.6M | 844k | 3.03 | |
| Clovis Oncology | 0.4 | $2.6M | 73k | 35.00 | |
| Community Health Systems (CYH) | 0.4 | $2.5M | 95k | 26.53 | |
| Tandem Diabetes Care | 0.4 | $2.5M | 209k | 11.81 | |
| Catabasis Pharmaceuticals | 0.4 | $2.4M | 306k | 7.93 | |
| Sagent Pharmaceuticals | 0.4 | $2.4M | 150k | 15.91 | |
| Omnicell (OMCL) | 0.3 | $2.3M | 74k | 31.08 | |
| Chimerix (CMRX) | 0.3 | $2.3M | 256k | 8.95 | |
| Tetraphase Pharmaceuticals | 0.3 | $2.3M | 225k | 10.03 | |
| Esperion Therapeutics (ESPR) | 0.3 | $2.2M | 100k | 22.26 | |
| Orexigen Therapeutics | 0.3 | $2.0M | 1.2M | 1.72 | |
| Regulus Therapeutics | 0.3 | $1.7M | 200k | 8.72 | |
| Array BioPharma | 0.2 | $1.6M | 370k | 4.22 | |
| Mirati Therapeutics | 0.2 | $1.6M | 50k | 31.60 | |
| Fibrogen | 0.2 | $1.5M | 50k | 30.48 | |
| Avalanche Biotechnologies In | 0.2 | $1.5M | 154k | 9.52 | |
| Dynavax Technologies (DVAX) | 0.2 | $1.3M | 55k | 24.16 | |
| Hologic (HOLX) | 0.2 | $1.3M | 33k | 38.68 | |
| Anthera Pharmaceutcls | 0.2 | $1.2M | 250k | 4.64 | |
| Bind Therapeutics | 0.1 | $306k | 134k | 2.29 | |
| Threshold Pharmaceuticals | 0.0 | $97k | 202k | 0.48 |
